Targeted therapies in thyroid cancer.

abstract：BACKGROUND:Sunitinib (S) is a multi-targeted tyrosine kinase inhibitor. It is synergistic with chemotherapy in preclinical models. We hypothesized that sunitinib in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) would be a tolerable and effective regimen in advanced gastric and gastroesophageal jun...

journal_title：Targeted oncology

authors： Mukherjee S,Fountzilas C,Boland PM,Gosain R,Attwood K,Tan W,Khushalani N,Iyer R

更新日期：2020-02-01 00:00:00

abstract：BACKGROUND:Tyrosine-kinase inhibitors (TKIs) markedly improve progression-free survival (PFS) of patients with advanced non-small-cell lung cancer (NSCLC) mutated for epidermal growth factor receptor (EGFR). Results on overall survival (OS) are less clear-cut. We performed a publication-based meta-analysis to address f...

journal_title：Targeted oncology

authors： Guetz GD,Landre T,Uzzan B,Chouahnia K,Nicolas P,Morere JF

更新日期：2016-02-01 00:00:00

abstract：:Atezolizumab (Tecentriq®), a humanized, anti-programmed cell death ligand-1 (PD-L1) monoclonal antibody, in combination with bevacizumab, carboplatin and paclitaxel (ABCP) or with carboplatin and nab-paclitaxel (ACnP) has been approved as first-line treatment for metastatic nonsquamous NSCLC, based on results from the...

journal_title：Targeted oncology

authors： Dhillon S,Syed YY

更新日期：2019-12-01 00:00:00

abstract：BACKGROUND:Peripheral T-cell lymphoma (PTCL) is associated with poor prognosis, particularly in patients with relapsed/refractory (R/R) disease. Pralatrexate, a folate analogue inhibitor, was the first drug approved to treat R/R PTCL. OBJECTIVE:As the distribution of PTCL subtypes differs between populations and few p...

journal_title：Targeted oncology

authors： Hong X,Song Y,Huang H,Bai B,Zhang H,Ke X,Shi Y,Zhu J,Lu G,Liebscher S,Cai C

更新日期：2019-04-01 00:00:00

abstract：:Hepatocellular carcinoma (HCC) is one of the most common forms of liver cancer diagnosed worldwide. HCC occurs due to chronic liver disease and is often diagnosed at advanced stages. Chemotherapeutic agents such as doxorubicin are currently used as first-line agents for HCC therapy, but these are non-selective cytotox...

journal_title：Targeted oncology

authors： Swamy SG,Kameshwar VH,Shubha PB,Looi CY,Shanmugam MK,Arfuso F,Dharmarajan A,Sethi G,Shivananju NS,Bishayee A

更新日期：2017-02-01 00:00:00

abstract：:ABP 980 was developed as a biosimilar to trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), that is indicated for the treatment of HER2-positive metastatic breast cancer, early breast cancer (EBC), and metastatic gastric cancer. ABP 980 is approved in the United States, Europ...

journal_title：Targeted oncology

authors： Kolberg HC,Colleoni M,Santi P,Demetriou GS,Segui-Palmer MA,Fujiwara Y,Hurvitz SA,Hanes V

更新日期：2019-12-01 00:00:00

abstract：:Desmoplastic small round cell tumor (DSRCT) is a rare and aggressive malignancy with poor outcome occurring in adolescents and young adults. Therapeutic options for patients with advanced disease are limited. Preclinical studies have shown that VEGFR-2 and VEGFA are overexpressed in DSRCT and that DSRCT xenografts wer...

journal_title：Targeted oncology

authors： Italiano A,Kind M,Cioffi A,Maki RG,Bui B

更新日期：2013-09-01 00:00:00

abstract：:Dynamic contrast-enhanced ultrasonography (DCE-US) is a new functional technique enabling a quantitative assessment of solid tumor perfusion using raw linear data. DCE-US allows the calculation of parameters as slope of wash-in or area under the curve (AUC) representing, respectively, blood flow or blood volume. Reduc...

journal_title：Targeted oncology

authors： Lassau N,Chebil M,Chami L,Bidault S,Girard E,Roche A

更新日期：2010-03-01 00:00:00

abstract：:It is believed that the insulin-like growth factor receptor type 1 (IGF-1R) signaling pathway plays a pivotal role in cancer growth, progression, and resistance to anticancer therapies. Strategies are being developed to block IGF-1R as an anticancer treatment. We reviewed several potential strategies for disrupting th...

journal_title：Targeted oncology

authors： Atzori F,Traina TA,Ionta MT,Massidda B

更新日期：2009-12-01 00:00:00

abstract：BACKGROUND:A consistent percentage of patients with metastatic non-small cell lung cancer (NSCLC) derives no or only marginal benefit from immunotherapy (IO). OBJECTIVE:Since serum sodium has been linked to both prognosis in NSCLC and modulation of immune cells activity, we aimed to assess the association between low ...

journal_title：Targeted oncology

authors： Fucà G,Galli G,Poggi M,Lo Russo G,Proto C,Imbimbo M,Vitali M,Ganzinelli M,Lanti C,Molino G,Stangoni F,Zilembo N,de Braud F,Garassino MC,Signorelli D

更新日期：2018-12-01 00:00:00

abstract：:With the incorporation of targeted therapies in routine cancer therapy, it is imperative that the array of toxicities associated with these agents be well-recognized and managed, especially since these toxicities are distinct from those seen with conventional cytotoxic agents. This review will focus on these renal tox...

journal_title：Targeted oncology

authors： Abbas A,Mirza MM,Ganti AK,Tendulkar K

更新日期：2015-12-01 00:00:00

abstract：:Non-small cell lung cancer (NSCLC) has recently been associated with interesting molecular characteristics that have important implications in carcinogenesis and response to targeted therapies. Targeted therapies, if given to a patient subpopulation enriched by the presence of relevant molecular targets, can often abr...

journal_title：Targeted oncology

authors： Planchard D

更新日期：2013-03-01 00:00:00

abstract：:Among neuroendocrine carcinomas of the gut, well-differentiated tumors are highly vascularized, featuring specific characteristics on contrast-enhanced imaging. Well-differentiated neuroendocrine tumors spontaneously harbor hypervascular enhancement, coexisting with areas of necrosis mainly located at the center of tu...

journal_title：Targeted oncology

authors： Faivre S,Ronot M,Dreyer C,Serrate C,Hentic O,Bouattour M,Bruno O,Couvelard A,Vilgrain V,Raymond E

更新日期：2012-06-01 00:00:00

abstract：:The influence of tumor infiltrating lymphocytes on tumor growth and response to therapy is becoming increasingly apparent. While much work has focused on the role of T cell responses in anti-tumor immunity, the role of B cells in solid tumors is much less understood. Tumor infiltrating B cells have been found in a var...

journal_title：Targeted oncology

authors： Flynn NJ,Somasundaram R,Arnold KM,Sims-Mourtada J

更新日期：2017-04-01 00:00:00

abstract：:Obinutuzumab (Gazyva®, Gazyvaro®) is a recombinant, monoclonal, humanized and glycoengineered, type II, anti-CD20, IgG1 antibody. It has recently been granted an additional indication for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen. In the...

journal_title：Targeted oncology

authors： Dhillon S

更新日期：2017-04-01 00:00:00

abstract：:Chemotherapy represents the mainstay of non-small cell lung cancer (NSCLC) treatment, but response is usually observed in only one out of three patients. Massive efforts have been carried out to identify biomarkers that might help clinicians to choose appropriate drugs, by identifying potentially sensitive subjects an...

journal_title：Targeted oncology

authors： Toschi L,Cappuzzo F

更新日期：2010-03-01 00:00:00

abstract：:In subsets of gastrointestinal stromal tumors (GISTs), mutations of the KIT and PDGFRA receptor tyrosine kinases correlate with tumor prognosis and response to tyrosine kinase inhibitors (TKIs). Determining genotypes in TKI-resistant GISTs is challenging due to the potential risks and limitations of repeated biopsies ...

journal_title：Targeted oncology

authors： Kang G,Bae BN,Sohn BS,Pyo JS,Kang GH,Kim KM

更新日期：2015-12-01 00:00:00

abstract：:In anticancer drug development, there has been increasing consideration for the potential of a compound to cause adverse electrocardiographic changes, especially QT interval prolongation, which can be associated with risk of torsades de pointes and sudden death. Irrespective of overt clinical toxicities, QTc assessmen...

journal_title：Targeted oncology

authors： Locatelli M,Criscitiello C,Esposito A,Minchella I,Goldhirsch A,Cipolla C,Curigliano G

更新日期：2015-03-01 00:00:00

abstract：:The First-Line Erbitux in Lung Cancer (FLEX) trial showed that the addition of cetuximab to chemotherapy followed by weekly cetuximab maintenance significantly improved survival in the first-line treatment of advanced non-small cell lung cancer (NSCLC). The phase IIIb NSCLC Erbitux Trial (NEXT) trial (NCT00820755) inv...

journal_title：Targeted oncology

authors： Heigener DF,Pereira JR,Felip E,Mazal J,Manzyuk L,Tan EH,Merimsky O,Sarholz B,Esser R,Gatzemeier U

更新日期：2015-06-01 00:00:00

abstract：BACKGROUND:Lung cancer harboring epidermal growth factor receptor (EGFR) mutations and treated with EGFR tyrosine kinase inhibitors (TKIs) all eventually develop acquired resistance to the treatment, with half of the patients developing EGFR T790M resistance mutations. OBJECTIVE:The purpose of this study was to assess...

journal_title：Targeted oncology

authors： Cardona AF,Arrieta O,Zapata MI,Rojas L,Wills B,Reguart N,Karachaliou N,Carranza H,Vargas C,Otero J,Archila P,Martín C,Corrales L,Cuello M,Ortiz C,Pino LE,Rosell R,Zatarain-Barrón ZL,CLICaP.

更新日期：2017-08-01 00:00:00

abstract：:The advent of imatinib mesilate, an oral target therapy, has dramatically changed the natural history of gastrointestinal stromal tumours (GISTs). This rare neoplasm has become the paradigm of targeted therapies in solid tumours, also introducing a home-based cure concept in oncology. However, it should be retained th...

journal_title：Targeted oncology

authors： Saponara M,Pantaleo MA,Nannini M,Biasco G

更新日期：2012-12-01 00:00:00

abstract：:Despite recent advances that have been made in the therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC), effective management of bone metastases remains a key goal not yet reached. The receptor tyrosine kinase MET and the vascular endothelial growth factor receptor (VEGFR) seem to play an i...

journal_title：Targeted oncology

authors： Modena A,Massari F,Ciccarese C,Brunelli M,Santoni M,Montironi R,Martignoni G,Tortora G

更新日期：2016-08-01 00:00:00

abstract：:Mesothelin is a tumor differentiation antigen, which is highly expressed in several solid neoplasms, including pancreatic cancer. Its selective expression on malignant cells and on only a limited number of healthy tissues has made it an interesting candidate for investigation as a diagnostic and prognostic biomarker a...

journal_title：Targeted oncology

authors： Nichetti F,Marra A,Corti F,Guidi A,Raimondi A,Prinzi N,de Braud F,Pusceddu S

更新日期：2018-06-01 00:00:00

abstract：:The discovery of chemoresistant cancer stem cells (CSCs) in carcinomas has created the need for therapies that specifically target these subpopulations of cells. Here, we characterized a bispecific targeted toxin that is composed of two antibody fragments and a catalytic protein toxin allowing it to bind two CSC marke...

journal_title：Targeted oncology

authors： Waldron NN,Barsky SH,Dougherty PR,Vallera DA

更新日期：2014-09-01 00:00:00

abstract：BACKGROUND:Axitinib, an inhibitor of vascular endothelial growth factor (VEGF) receptors, is approved as second-line treatment for advanced renal cell carcinoma (RCC). Agents targeting the VEGF pathway may induce renal toxicities, which may be influenced by pre-existing renal dysfunction. OBJECTIVE:The objective was t...

journal_title：Targeted oncology

authors： Chen Y,Rini BI,Motzer RJ,Dutcher JP,Rixe O,Wilding G,Stadler WM,Tarazi J,Garrett M,Pithavala YK

更新日期：2016-04-01 00:00:00

abstract：:The ubiquitin (Ub)+proteasome proteolytic pathway is responsible for the selective degradation of the majority of nuclear and cytosolic proteins. The proteasome is a high molecular weight multicatalytic protease that serves as the catalytic core of the complex Ub-dependent protein degradation pathway and is an excitin...

journal_title：Targeted oncology

authors： Driscoll JJ,Dechowdhury R

更新日期：2010-12-01 00:00:00

abstract：BACKGROUND:The identification of prognostic and/or predictive biomarkers for response to immune checkpoint inhibitors (ICI) could help guide treatment decisions. OBJECTIVE:We assessed changes in programmed cell death-1 (PD1)/PD1 ligand (PDL1) expression in key immunomodulatory cell subsets (myeloid-derived suppressor ...

journal_title：Targeted oncology

authors： Tzeng A,Diaz-Montero CM,Rayman PA,Kim JS,Pavicic PG Jr,Finke JH,Barata PC,Lamenza M,Devonshire S,Schach K,Emamekhoo H,Ernstoff MS,Hoimes CJ,Rini BI,Garcia JA,Gilligan TD,Ornstein MC,Grivas P

更新日期：2018-10-01 00:00:00

abstract：:Basal transcription regulation of the epidermal growth factor receptor is dependent upon a CA simple sequence repeat polymorphism in the intron-1 (CA-SSR-1). Here, we evaluate the role of CA-SSR-1 in complete resected esophageal cancer (EC) patients without neoadjuvant or adjuvant treatment. Genomic DNA was extracted ...

journal_title：Targeted oncology

authors： Vashist YK,Trump F,Gebauer F,Kutup A,Güngör C,Kalinin V,Muddasar R,Vettorazzi E,Yekebas EF,Brandt B,Pantel K,Izbicki JR

更新日期：2014-03-01 00:00:00

abstract：BACKGROUND:Immunotherapy based on programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has revolutionized the treatment of non-small cell lung cancer (NSCLC). Patients with high PD-L1 expression or DNA mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) cancer are re...

journal_title：Targeted oncology

authors： Huang D,Zhang F,Tao H,Zhang S,Ma J,Wang J,Liu Z,Cui P,Chen S,Huang Z,Wu Z,Zhao L,Hu Y

更新日期：2020-02-01 00:00:00

abstract：:The selective BRAF inhibitors vemurafenib and dabrafenib yield high response rates and improved overall survival in patients with BRAF V600E-mutant metastatic melanoma. Treatment traditionally continues until disease progression or the development of unacceptable toxicity. Acquired drug resistance and toxicity are key...

journal_title：Targeted oncology

authors： Dooley AJ,Gupta A,Middleton MR

更新日期：2016-08-01 00:00:00